USPTO Art Unit 1658 Prosecution Statistics

Art Unit Information

Art Unit: 1658
Group: 1650
Tech Center: 1600
Total Cases: 4,777
Last Active: June 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19235902VASCULAR EMBOLIC SYSTEMJune 2025February 2026Allow810NoNo
19217808METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPYMay 2025March 2026Allow921YesNo
19207094LEPTIN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME TO SUPPORT WEIGHT LOSS AND/OR MAINTENANCEMay 2025September 2025Allow511NoNo
19200045METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERSMay 2025March 2026Abandon1010NoNo
19192339ANTIMICROBIAL PEPTIDE AND APPLICATION THEREOFApril 2025February 2026Abandon1001NoNo
19174121SEMAGLUTIDE IN MEDICAL THERAPYApril 2025December 2025Allow820NoNo
19173198INTERLEUKIN-15 SUPERAGONIST N-803 IN PEOPLE EXPERIENCING LONG COVIDApril 2025February 2026Abandon1010YesNo
19172886PAM3CSK4 INJECTION FOR THE PREVENTION AND MANAGEMENT OF MASLDApril 2025October 2025Allow601YesNo
19082426SENESCENCE INHIBITORMarch 2025January 2026Allow1020NoNo
19044943INSECT NEUROPEPTIDES 8February 2025October 2025Allow811NoNo
19024178FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTIONJanuary 2025October 2025Abandon901NoNo
19023048PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDESJanuary 2025April 2025Allow310YesNo
18960248INSECT NEUROPEPTIDES 9November 2024November 2025Allow1121YesNo
18955985HANGTAIMYCIN DERIVATIVES AND THEIR PREPARATION METHODS AND APPLICATIONNovember 2024September 2025Allow1021YesNo
18954145ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH)November 2024December 2025Allow1221YesNo
18917707ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEOctober 2024February 2025Allow410NoNo
18912061INSECT NEUROPEPTIDES 6October 2024May 2025Allow711YesNo
18906616BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4October 2024September 2025Allow1221YesNo
18853789Treatment for Ocular FibrosisOctober 2024July 2025Allow1001NoNo
18903864THERAPEUTIC POLYPEPTIDEOctober 2024April 2025Allow601NoNo
18893357INCRETIN ANALOGS AND USES THEREOFSeptember 2024March 2025Allow611NoNo
18883592Long-Acting GLP-1 CompoundSeptember 2024October 2025Abandon1311NoNo
18829844PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOFSeptember 2024August 2025Allow1111NoNo
18820792SEMAGLUTIDE IN MEDICAL THERAPYAugust 2024February 2025Allow520NoNo
18812797GLP-1/GIP DUAL AGONISTSAugust 2024August 2025Allow1121NoNo
18806394PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDEAugust 2024February 2025Allow601NoNo
18834736USE OF COLLAGEN HYDROLYSATE IN PREVENTION AND/OR TREATMENT OF FOOD CRAVINGJuly 2024December 2025Allow1720YesNo
18834531Recombinant Humanized Collagen Type III Alpha-1, and Expression Vector and Use ThereofJuly 2024January 2026Allow1811NoNo
18783556METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1July 2024October 2025Abandon1520NoYes
18783777METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1July 2024September 2025Abandon1421NoNo
18774846COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERSJuly 2024January 2025Allow711NoNo
17855222ANTIBACTERIAL PRODUCTSJune 2024March 2026Abandon4421YesNo
18754189CYCLOPHILIN INHIBITORS AND USES THEREOFJune 2024September 2025Allow1411NoNo
18724136IL-4 DERIVED PEPTIDE FRAGMENTS FOR USE IN THE TREATMENT OF DIABETIC NEPHROPATHYJune 2024June 2025Allow1220NoNo
18751723NPY2 RECEPTOR AGONISTSJune 2024May 2025Allow1101NoNo
18722415ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASESJune 2024October 2025Allow1620YesNo
18749044EMBRYONIC ANGIOGENESIS MARKERS AND DIAGNOSTIC AND THERAPEUTIC STRATEGIES BASED THEREONJune 2024October 2025Allow1621NoNo
18742845MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOFJune 2024October 2025Allow1610NoNo
18719490DUAL TARGETING FOR CELL-SPECIFIC DELIVERY TO THE CENTRAL NERVOUS SYSTEMJune 2024August 2025Allow1520NoNo
18736608SEMAGLUTIDE IN MEDICAL THERAPYJune 2024January 2025Abandon700NoNo
18734820PEPTIDES, HYDROGEL COMPOSITIONS AND METHODS OF USE THEREOFJune 2024July 2025Allow1311NoNo
18666750STAPLED AND SPECIFICALLY TARGETED ANTIMICROBIAL PEPTIDEMay 2024November 2024Allow611NoNo
18660504NOVEL PEPTIDESMay 2024August 2024Allow300NoNo
18661201HUMAN AMYLIN ANALOG POLYPEPTIDES AND METHODS OF USEMay 2024October 2025Allow1711NoNo
18660826CELL PENETRATING PEPTIDEMay 2024October 2025Allow1710NoNo
18707536LIQUID FORMULATIONS OF AMYLIN ANALOGUESMay 2024December 2025Allow1920NoNo
18650574ANTI-AGING STURGEON ROE TETRAPEPTIDE AND PREPARATION METHOD AND APPLICATION THEREOFApril 2024April 2025Allow1111YesNo
18648015PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAMEApril 2024March 2026Abandon2211NoNo
18640676METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTSApril 2024October 2025Abandon1811NoNo
18639139ANTIFUNGAL PROTEIN COMPOSITIONApril 2024February 2026Abandon2201NoNo
18637124ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEApril 2024March 2025Allow1110NoNo
18636117ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICESApril 2024December 2025Allow2021NoNo
18632799COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGSApril 2024February 2025Allow1001YesNo
18627757COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTSApril 2024September 2025Allow1811YesNo
18626600SYSTEMS AND METHODS FOR TREATMENT OF HEARING USING DIHEXAApril 2024March 2025Allow1110NoNo
18697004TRICYCLIC POLYPEPTIDE CONJUGATED DRUG AND USE THEREOFMarch 2024October 2025Allow1901NoNo
18616600METHODS FOR TREATING CANCERS USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONSMarch 2024January 2025Allow1000YesNo
18615134METHODS AND COMPOSITIONS FOR TREATING MUCOSAL TISSUE DISORDERSMarch 2024March 2026Allow2411NoNo
18611711GENE PPARalpha FOR IMPROVING DISEASE RESISTANCE OF HALF-SMOOTH TONGUE SOLE CYNOGLOSSUS SEMILAEVIS AND USE THEREOFMarch 2024September 2025Abandon1811NoNo
18612627HUMAN COLLAGEN 17-TYPE POLYPEPTIDE, PRODUCTION METHOD THEREFOR AND USE THEREOFMarch 2024June 2025Allow1411NoNo
18612612HUMAN COLLAGEN 17-TYPE POLYPEPTIDE, PRODUCTION METHOD THEREFOR AND USE THEREOFMarch 2024June 2025Allow1411NoNo
18610009BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1)March 2024January 2026Abandon2201NoNo
18604451DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASEMarch 2024December 2025Abandon2211NoNo
18602255GLP-1/GIP DUAL AGONIST, PREPARATION METHOD AND USE THEREOFMarch 2024July 2025Allow1611YesNo
18602026AGENTS AND METHODS FOR TREATING CBP-DEPENDENT CANCERSMarch 2024October 2025Allow1921NoNo
18600947EGG WHITE PROTEIN ANTI-INFLAMMATORY PEPTIDE AND APPLICATION THEREOFMarch 2024October 2024Allow711YesNo
18601031COMPSTATIN ANALOGUES AND THEIR MEDICAL USESMarch 2024December 2025Allow2111NoNo
18598577METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTSMarch 2024October 2025Abandon1911NoNo
18596026THERAPEUTICS DIRECTED AGAINST CORONAVIRUSMarch 2024December 2025Abandon2221NoNo
18591918ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOFFebruary 2024May 2025Allow1501YesNo
18589590CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAMEFebruary 2024May 2025Allow1501YesNo
18590636STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTIONFebruary 2024April 2025Allow1310YesNo
18587927PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCEFebruary 2024October 2025Allow2011YesNo
18584321PEPTIDE USED FOR IMMUNOTHERAPEUTICSFebruary 2024July 2025Allow1721YesNo
18583562Peptide Synthesis in Aqueous SolutionFebruary 2024September 2025Abandon1921NoNo
18582180HETERODIMERIC FC CYTOKINES AND USES THEREOFFebruary 2024August 2024Allow611NoNo
18581115STAPLED ANTIMICROBIAL PEPTIDEFebruary 2024November 2024Allow901YesNo
18444111MODIFIED U6 PROMOTER SYSTEM FOR TISSUE SPECIFIC EXPRESSIONFebruary 2024September 2025Abandon1901NoNo
18444501Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereofFebruary 2024October 2024Allow801NoNo
18441502METHODS AND COMPOSITIONS FOR DETERMINING PLOIDYFebruary 2024February 2026Allow2411YesNo
18440920METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATEFebruary 2024August 2025Allow1820YesNo
18436212TREATMENT OF AGE-RELATED MACULAR DEGENERATIONFebruary 2024September 2025Abandon1910NoNo
18435934NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS FOR TREATING MUSCLE WASTING DISEASESFebruary 2024October 2025Abandon2011NoNo
18434731DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOFFebruary 2024December 2024Allow1110YesNo
18427270GLP-1 COMPOSITIONS AND USES THEREOFJanuary 2024September 2024Allow820YesNo
18426692READY-TO-USE BIVALIRUDIN COMPOSITIONSJanuary 2024September 2025Allow2011NoNo
18424386HETEROTANDEM BICYCLIC PEPTIDE COMPLEXJanuary 2024March 2025Allow1300NoNo
18423020ANTI-KRAS-G12D T CELL RECEPTORSJanuary 2024April 2025Allow1511NoNo
18422878COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTORJanuary 2024June 2025Allow1711NoNo
18420332Treatment of AscitesJanuary 2024September 2025Abandon2021NoYes
18415952BIOLOGICAL ACTIVE PEPTIDE FOR IMPROVING ENZYME ACTIVITY OF ACE2 AND APPLICATION THEREOFJanuary 2024January 2025Allow1220NoNo
18415415MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOFJanuary 2024January 2026Allow2411NoNo
18413417AQUEOUS PEPTIDE PROGRAMMING OF THE VINYLIDENE FLUORIDE FERROELECTRIC PHASEJanuary 2024January 2026Allow2421YesNo
18413390TOPICAL COMPOSITIONS CONTAINING N-ACYL DIPEPTIDE DERIVATIVES AND GLYCOLIC ACIDJanuary 2024October 2025Abandon2121NoNo
18414112MODIFIED ANTI-INFLAMMATORY PROTEINS AND METHOD OF USEJanuary 2024June 2025Allow1710YesNo
18412406NEW METHODS AND SYSTEMS FOR TARGETED GENE MANIPULATIONJanuary 2024January 2026Allow2411NoNo
18411838ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAMEJanuary 2024February 2026Abandon2521NoNo
18578613SELF-ASSEMBLING PEPTIDE AMPHIPHILES DISPLAYING A TRANSFORMING GROWTH FACTOR BETA 1 (TGF-ß1) MIMETIC EPITOPEJanuary 2024December 2025Allow2321NoNo
18405731IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCERJanuary 2024April 2025Abandon1510NoNo
18390354MOLECULAR GUIDE SYSTEM PEPTIDES AND USES THEREOFDecember 2023June 2025Allow1821NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1658.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
93
Examiner Affirmed
61
(65.6%)
Examiner Reversed
32
(34.4%)
Reversal Percentile
61.1%
Higher than average

What This Means

With a 34.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
435
Allowed After Appeal Filing
83
(19.1%)
Not Allowed After Appeal Filing
352
(80.9%)
Filing Benefit Percentile
5.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1658 - Prosecution Statistics Summary

Executive Summary

Art Unit 1658 is part of Group 1650 in Technology Center 1600. This art unit has examined 4,777 patent applications in our dataset, with an overall allowance rate of 63.0%. Applications typically reach final disposition in approximately 31 months.

Comparative Analysis

Art Unit 1658's allowance rate of 63.0% places it in the 18% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1658 receive an average of 2.00 office actions before reaching final disposition (in the 59% percentile). The median prosecution time is 31 months (in the 47% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.